RETINOIDS & RECEPTORS IN BLADDER CANCER CHEMOPREVENTION
类维生素A
基本信息
- 批准号:6475944
- 负责人:
- 金额:$ 15.22万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1998
- 资助国家:美国
- 起止时间:1998-09-30 至 2003-11-30
- 项目状态:已结题
- 来源:
- 关键词:apoptosis biomarker bladder neoplasm cancer prevention cell differentiation cell growth regulation cell line chemoprevention drug interactions fenretinide human tissue in situ hybridization keratin polymerase chain reaction receptor expression urinary bladder epithelium vitamin receptor western blottings
项目摘要
DESCRIPTION: (Applicant's Description) Bladder cancer is the 6th most
common cancer in the developed world. More than 50,000 new cases of bladder
cancer and 11,200 deaths from this cancer occur each year in the United
States. Bladder carcinogenesis, like oral premalignancy, is an excellent
model for chemopreventive study. Natural and synthetic retinoids have been
tested as chemopreventive and chemotherapeutic agents against oral tumors,
but the effects of these retinoids on bladder cancers are not well
documented. The objective of the proposed study is to explore the
feasibility of using natural or synthetic retinoids in the prevention and
treatment Of bladder cancer and to investigate the mechanisms of retinoids
in this setting. The effect of different retinoids on cell growth,
differentiation, apoptosis, and expression of retinoic acid receptors (RARs)
in bladder cancer cell lines and normal bladder epithelial cells in
short-term cultures will be studied. The hypotheses are: a) retinoids
inhibit the growth of bladder cancer cells partially through the induction
of apoptosis; b) RARs, especially RARB, play a role in regulating the growth
and differentiation of bladder cancer cells; and C) some receptors are
down-regulated in certain bladder cancers and can be up-regulated by
retinoids in vivo. The hypotheses will be examined by fulfilling the
following specific aims: 1) to evaluate the effects of different retinoids
on growth and differentiation in normal bladder epithelial cells and bladder
cancer cells by examining morphology, cell cycle, and the expression of
cytokeratins 4, 7, 8, 13, 18, and 19 using western blotting; 2) to determine
the effects of different retinoids on the induction of apoptosis in bladder
cancer cells by using DNA fragmentation, propidium iodide staining, and
terminal deoxynucleotidyl transferase assays and the effects of combinations
of RAR-selective and retinoid X receptor (RXR)-selective retinoids on growth
inhibition and apoptosis to find possible additive or synergistic actions of
these compounds; 3) to examine the expression of retinoid receptors and
their induction by different retinoids in normal bladder epithelial cells
and bladder cancer cells by using reverse-transcriptase polymerase chain
reaction and western blotting to determine the relationship between receptor
expression and the chemopreventive effect of different retinoids; and 4) to
analyze the expression of retinoid receptors in bladder cancer specimens
before and after chemoprevention with 4-(hydroxyphenyl)retinamide (4HPR) by
in situ hybridization and polymerase chain reaction. The results of these
studies are expected to increase our understanding of the mechanisms of
action and potential usefulness of new retinoids in bladder cancer
chemoprevention.
描述:(申请人描述)膀胱癌是第六大癌症
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHANGPING ZOU其他文献
CHANGPING ZOU的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHANGPING ZOU', 18)}}的其他基金
STRUCTURAL STUDIES OF FOLLISTATIN ISOFORMS BY SAXS IN SOLUTION
通过溶液中的 SAXS 进行卵泡抑素异构体的结构研究
- 批准号:
8362255 - 财政年份:2011
- 资助金额:
$ 15.22万 - 项目类别:
STRUCTURAL STUDIES OF FOLLISTATIN ISOFORMS BY SAXS IN SOLUTION
通过溶液中的 SAXS 进行卵泡抑素异构体的结构研究
- 批准号:
8170238 - 财政年份:2010
- 资助金额:
$ 15.22万 - 项目类别:
RETINOIDS & RECEPTORS IN BLADDER CANCER CHEMOPREVENTION
类维生素A
- 批准号:
6328987 - 财政年份:1998
- 资助金额:
$ 15.22万 - 项目类别:
RETINOIDS & RECEPTORS IN BLADDER CANCER CHEMOPREVENTION
类维生素A
- 批准号:
6124484 - 财政年份:1998
- 资助金额:
$ 15.22万 - 项目类别:
RETINOIDS & RECEPTORS IN BLADDER CANCER CHEMOPREVENTION
类维生素A
- 批准号:
2696356 - 财政年份:1998
- 资助金额:
$ 15.22万 - 项目类别:
RETINOIDS & RECEPTORS IN BLADDER CANCER CHEMOPREVENTION
类维生素A
- 批准号:
2899609 - 财政年份:1998
- 资助金额:
$ 15.22万 - 项目类别:
RETINOIDS & RECEPTORS IN BLADDER CANCER CHEMOPREVENTION
类维生素A
- 批准号:
6747797 - 财政年份:1998
- 资助金额:
$ 15.22万 - 项目类别:
相似国自然基金
基于DNA甲基化交互网络的癌症hallmark挖掘及其在癌症转移biomarker筛选中的应用
- 批准号:61602201
- 批准年份:2016
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
血清miRNAs成为一种新的biomarker在PD诊断中的价值和LRRK2基因调控的机制研究
- 批准号:81170309
- 批准年份:2011
- 资助金额:50.0 万元
- 项目类别:面上项目
非小细胞肺癌Biomarker的Imaging MS研究新方法
- 批准号:30672394
- 批准年份:2006
- 资助金额:30.0 万元
- 项目类别:面上项目
相似海外基金
酸化ストレス応答アポトーシス誘導蛋白のUCに対する新規Biomarker探索と治療への展開
寻找治疗 UC 的氧化应激反应性凋亡诱导蛋白的新生物标志物并开发治疗方法
- 批准号:
24K11919 - 财政年份:2024
- 资助金额:
$ 15.22万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
肝内胆管癌新規Biomarkerの同定及び癌周囲間質を標的とした新規治療開発
鉴定肝内胆管癌的新型生物标志物并开发针对癌周基质的新疗法
- 批准号:
24K19350 - 财政年份:2024
- 资助金额:
$ 15.22万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
収縮能が保たれた心不全の機械学習分類とmicroRNAなどのbiomarkerの探索
机器学习对具有保留收缩性的心力衰竭进行分类并搜索 microRNA 等生物标志物
- 批准号:
24K19007 - 财政年份:2024
- 资助金额:
$ 15.22万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Development of a predictive biomarker for Parkinson's disease
帕金森病预测生物标志物的开发
- 批准号:
MR/Y019415/1 - 财政年份:2024
- 资助金额:
$ 15.22万 - 项目类别:
Research Grant
Sleep and circadian dysfunction in ageing and neurodegeneration: a life course and biomarker study of the British 1946 birth cohort.
衰老和神经退行性疾病中的睡眠和昼夜节律功能障碍:对英国 1946 年出生队列的生命历程和生物标志物研究。
- 批准号:
MR/Y009452/1 - 财政年份:2024
- 资助金额:
$ 15.22万 - 项目类别:
Fellowship
Biomarker-Based Platform for Early Diagnosis of Chronic Liver Disease to Enable Personalized Therapy (LIVERAIM)
基于生物标志物的慢性肝病早期诊断平台,以实现个性化治疗(LIVERAIM)
- 批准号:
10087822 - 财政年份:2024
- 资助金额:
$ 15.22万 - 项目类别:
EU-Funded
Enhanced stratification of COPD patients via integration of a digitally enabled biomarker Point-of-Care test within a Remote Patient Monitoring tool
通过在远程患者监测工具中集成数字化生物标志物即时检测,增强 COPD 患者的分层
- 批准号:
10098600 - 财政年份:2024
- 资助金额:
$ 15.22万 - 项目类别:
Collaborative R&D
QuBIE: Quantitative Biomarker Identification for Non-Endoscopic Prediction and Monitoring of Treatment Response in Eosinophilic Oesophagitis
QuBIE:用于非内镜预测和监测嗜酸性食管炎治疗反应的定量生物标志物鉴定
- 批准号:
10083253 - 财政年份:2024
- 资助金额:
$ 15.22万 - 项目类别:
Collaborative R&D
膵癌腫瘍内線維化に着目した術前化学療法効果予測に関する画像biomarkerの確立
建立预测胰腺癌瘤内纤维化术前化疗效果的影像生物标志物
- 批准号:
24K18824 - 财政年份:2024
- 资助金额:
$ 15.22万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Multi-modal non-invasive biomarker screening for high-risk undiagnosed liver disease
针对高危未确诊肝病的多模式非侵入性生物标志物筛查
- 批准号:
10073169 - 财政年份:2023
- 资助金额:
$ 15.22万 - 项目类别:
Collaborative R&D














{{item.name}}会员




